Skip to Content

Jazz Pharmaceuticals PLC JAZZ Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 129.44
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Value
  • Day Range 127.98  –  129.38
  • Year Range 120.64  –  160.96
  • Market Cap 8.1131 Bil
  • Volume / Avg 195,579.0 /  486,496.0
  • Price / Sales 2.33
  • Price / Book 2.33
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis JAZZ

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Jazz Pharmaceuticals Remains Focused on Commercial Execution

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

Jazz Pharmaceuticals added its leading drug, Xyrem, to its portfolio in 2005 with the acquisition of Orphan Medical for about $123 million. This was a great price for the then newly approved drug, which became a blockbuster. At that point, Xyrem was the only approved treatment for cataplexy (sudden muscle weakness or paralysis) in narcolepsy; it has since garnered additional approvals for excessive daytime sleepiness in patients with narcolepsy. Its strong efficacy has propelled its success in the difficult-to-treat sleep indication, but generic entry is on the horizon, leaving a cloud of uncertainty for the company. Jazz reached a settlement in 2017 with Hikma Pharmaceuticals to not allow generics on the market until January 2023. While Jazz will retain some economic profit from royalties on generic sales and a shared distribution program, we expect its returns to decline following Xyrem's generic entry.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics JAZZ

Company Profile JAZZ

Business Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Waterloo Road, Fifth Floor, Waterloo Exchange
Dublin, D04 E5W7, IRL
Industry Biotechnology
Employees 2,800

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of JAZZ’s competitive advantage.

Jazz Pharmaceuticals PLC


Exelixis Inc




Genmab A/S

−$0.94 (0.72%) +$0.12 (0.55%) +$0.30 (0.39%) −$64.00 (2.55%)
Market Cap
8.11 Bil6.99 Bil14.77 Bil159.62 Bil
Biotechnology Biotechnology Biotechnology Biotechnology

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Jazz Pharmaceuticals PLC Stock

No. JAZZ does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

JAZZ’s market cap is 8.11 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

JAZZ’s stock style is Mid Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

JAZZ’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare JAZZ’s historical performance against its industry peers and the overall market.